EPLIN was significantly decreased in cells of more mesenchymal morphology (known as the androgen refractory cancer of the prostate (ARCaPM) cell lineage model), suggesting that EPLIN downregulation is directly implicated in EMT, along with the cadherin–catenin complex [47]. Here, LIMA1 is linked to refractory malignant neoplasm.